Physician profile
Malika George
NPI 1467603183
$3,873.36
in general payments reported to CMS, 2019-2025
23 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $833 · 2020: $669 · 2021: $604 · 2022: $379 · 2023: $656 · 2024: $430 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,388.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $757.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $715.15 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $410.37 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $376.08 | 2019-2024 | Farxiga |
| Amarin Pharma, INC. | $298.86 | 2019-2022 | |
| Lilly USA, LLC | $271.21 | 2019-2024 | Zepbound, Jardiance, Mounjaro |
| Abbott Laboratories | $241.40 | 2022-2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $203.99 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $120.50 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $88.98 | 2019-2020 | |
| Amgen INC. | $78.43 | 2019-2024 | Otezla, Repatha |
| Pfizer INC. | $61.24 | 2023-2024 | |
| Glaxosmithkline, LLC. | $37.02 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.38 | 2023-2024 | |
| Antares Pharma, INC. | $31.84 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $24.75 | 2024 | |
| Smith+Nephew, INC. | $24.07 | 2023 | Pico, Renasys Go V2 Home |
| Genentech USA, INC. | $18.66 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.68 | 2022 | |
| Esperion Therapeutics, INC. | $16.54 | 2020 | |
| Averitas Pharma INC. | $16.38 | 2024 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.45 | 2020 | |
| Exact Sciences Corporation | $13.10 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malika George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.